Inverness Medical Innovations Plans Move to NYSE

WALTHAM, Mass., Dec. 22 Inverness MedicalInnovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics,monitoring and health management solutions, announced today that it intends tomove the trading of its listed securities to the New York Stock Exchange(NYSE). The Company has filed its listing application with NYSE and currentlyexpects its listings on NYSE to commence on January 6, 2009. Until that timethe Company's shares will continue to trade on Alternext (formerly theAmerican Stock Exchange). The Company's Common Stock will continue to tradeunder the symbol, "IMA" and its Series B Convertible Perpetual Preferred Stockwill continue to trade under the symbol, "IMA.PR.B".

"We are proud to be able to move our listings over to the New York StockExchange and offer our shareholders the increased liquidity and visibilityavailable through this premier exchange," said Ron Zwanziger, Inverness'Chairman, Chief Executive Officer and President. "We look forward to a longand successful relationship with NYSE."

"We are pleased to welcome Inverness, a leader in medical diagnosticsproducts and health management, to our family of listed companies," saidDuncan Niederauer, NYSE Euronext CEO. "Inverness recognizes the value andbenefits of listing on the NYSE, and we look forward to serving the companyand its shareholders."

By developing new capabilities in near-patient diagnosis, monitoring andhealth management, Inverness Medical Innovations enables individuals to takecharge of improving their health and quality of life. A global leader in rapidpoint-of-care diagnostics, Inverness' products, as well as its new productdevelopment efforts, focus on infectious disease, cardiology, oncology, drugsof abuse and women's health. Inverness is headquartered in Waltham,Massachusetts.

For more information about Inverness Medical Innovations, please visit ourwebsite at http://www.invernessmedical.com.

This press release may contain forward-looking statements within themeaning of the federal securities laws, including statements regarding plannedmovement of the companies securities listings to the NYSE, the expect timingof the listing and the potential benefits of the change. These statementsreflect Inverness' current views with respect to future events and are basedon its management's current assumptions and information currently available.Actual results may differ materially due to numerous factors including,without limitation, risks associated with NYSE application and review process;and the risks and uncertainties described in Inverness' annual report on Form10-K, and other factors identified from time to time in its periodic filingswith the Securities and Exchange Commission. Inverness undertakes noobligation to update any forward-looking statements contained herein.

SOURCE Inverness Medical Innovations, Inc.

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...